{"id":"W2806145489","doi":"10.1200/jco.2018.36.18_suppl.lba9000","title":"IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Carboplatin; Atezolizumab; Paclitaxel; Internal medicine; Docetaxel; Oncology; Population; Chemotherapy; Cisplatin; Cancer; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003996267,0.00195401,0.002128435,0.0005593949,0.0003488872,0.001137018,0.001455436,0.00171097,0.007653197],"category_scores_gemma":[0.003137473,0.0008376752,0.002371489,0.0005174404,0.001211517,0.001206106,0.0009487112,0.003913098,0.0009463022],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001375762,"about_ca_system_score_gemma":0.001808351,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005335255,"about_ca_topic_score_gemma":0.002049777,"domain_scores_codex":[0.9984183,0.001081094,0.00005996828,0.0001484048,0.0001368899,0.0001552889],"domain_scores_gemma":[0.9983227,0.0004766561,0.0004376783,0.0001476174,0.00006341029,0.0005518897],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.945632,0.01563213,0.002758953,0.0006716956,0.001590521,0.00007871568,0.00007702198,0.001067009,0.005909746,0.000211561,0.002601244,0.02376935],"study_design_scores_gemma":[0.8177143,0.1695153,0.0070125,0.00003869672,0.00128117,0.0001136733,0.00001937095,0.001135021,0.001321552,0.0002546559,0.001563952,0.00002988024],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818596,0.002672656,0.001247307,0.0009140963,0.0001913243,0.00596468,0.003769179,0.0001691428,0.003211912],"genre_scores_gemma":[0.9824817,0.001249971,0.001863732,0.001204944,0.0002834939,0.005058701,0.004974707,0.00005301697,0.002829714],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007653197,"threshold_uncertainty_score":0.02560252,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05384313562783741,"score_gpt":0.4520079957856368,"score_spread":0.3981648601577993,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}